Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 4.08
NAS:ARRY's Cash-to-Debt is ranked lower than
66% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. NAS:ARRY: 4.08 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ARRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.69 Max: No Debt
Current: 4.08
0.49
No Debt
Equity-to-Asset 0.53
NAS:ARRY's Equity-to-Asset is ranked lower than
69% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ARRY: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ARRY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.55  Med: 0.23 Max: 0.93
Current: 0.53
-1.55
0.93
Debt-to-Equity 0.41
NAS:ARRY's Debt-to-Equity is ranked lower than
63% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:ARRY: 0.41 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ARRY' s Debt-to-Equity Range Over the Past 10 Years
Min: -18.96  Med: -0.31 Max: 18.79
Current: 0.41
-18.96
18.79
Debt-to-EBITDA -0.97
NAS:ARRY's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. NAS:ARRY: -0.97 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:ARRY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.99  Med: -1.41 Max: 4.67
Current: -0.97
-12.99
4.67
Piotroski F-Score: 4
Altman Z-Score: 8.61
Beneish M-Score: -2.34
WACC vs ROIC
15.35%
145.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -63.52
NAS:ARRY's Operating Margin % is ranked higher than
51% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. NAS:ARRY: -63.52 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ARRY' s Operating Margin % Range Over the Past 10 Years
Min: -410.11  Med: -93.28 Max: -12.98
Current: -63.52
-410.11
-12.98
Net Margin % -72.33
NAS:ARRY's Net Margin % is ranked lower than
51% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. NAS:ARRY: -72.33 )
Ranked among companies with meaningful Net Margin % only.
NAS:ARRY' s Net Margin % Range Over the Past 10 Years
Min: -511.63  Med: -83.68 Max: 18.05
Current: -72.33
-511.63
18.05
ROE % -80.48
NAS:ARRY's ROE % is ranked lower than
81% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. NAS:ARRY: -80.48 )
Ranked among companies with meaningful ROE % only.
NAS:ARRY' s ROE % Range Over the Past 10 Years
Min: -3933.07  Med: -132.15 Max: 110.67
Current: -80.48
-3933.07
110.67
ROA % -31.16
NAS:ARRY's ROA % is ranked lower than
54% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. NAS:ARRY: -31.16 )
Ranked among companies with meaningful ROA % only.
NAS:ARRY' s ROA % Range Over the Past 10 Years
Min: -99.03  Med: -51.46 Max: 5.6
Current: -31.16
-99.03
5.6
ROC (Joel Greenblatt) % -1455.76
NAS:ARRY's ROC (Joel Greenblatt) % is ranked lower than
68% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. NAS:ARRY: -1455.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ARRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1455.76  Med: -321.97 Max: 291.72
Current: -1455.76
-1455.76
291.72
3-Year Revenue Growth Rate 39.40
NAS:ARRY's 3-Year Revenue Growth Rate is ranked higher than
84% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. NAS:ARRY: 39.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ARRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: -2.2 Max: 39.8
Current: 39.4
-35.9
39.8
3-Year EBITDA Growth Rate -3.00
NAS:ARRY's 3-Year EBITDA Growth Rate is ranked lower than
59% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. NAS:ARRY: -3.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ARRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.85 Max: 68.6
Current: -3
0
68.6
3-Year EPS without NRI Growth Rate -1.40
NAS:ARRY's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NAS:ARRY: -1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ARRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.95 Max: 50.5
Current: -1.4
0
50.5
GuruFocus has detected 4 Warning Signs with Array BioPharma Inc NAS:ARRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ARRY's 30-Y Financials

Financials (Next Earnings Date: 2018-08-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

ARRY Guru Trades in Q2 2017

Paul Tudor Jones 73,373 sh (New)
Jim Simons 990,441 sh (New)
Steven Cohen 2,406,000 sh (+88.28%)
Ken Fisher 134,180 sh (+71.99%)
Caxton Associates Sold Out
» More
Q3 2017

ARRY Guru Trades in Q3 2017

Louis Moore Bacon 100,000 sh (New)
Steven Cohen 9,008,999 sh (+274.44%)
Paul Tudor Jones 75,184 sh (+2.47%)
Ken Fisher 134,180 sh (unchged)
Jim Simons Sold Out
» More
Q4 2017

ARRY Guru Trades in Q4 2017

Pioneer Investments 54,900 sh (New)
Jim Simons 712,671 sh (New)
Ken Fisher 161,433 sh (+20.31%)
Steven Cohen 1,020,900 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen 5,712,626 sh (-36.59%)
Paul Tudor Jones 12,834 sh (-82.93%)
» More
Q1 2018

ARRY Guru Trades in Q1 2018

George Soros 526,500 sh (New)
Leon Cooperman 200,000 sh (New)
Paul Tudor Jones 76,307 sh (+494.57%)
Pioneer Investments Sold Out
Ken Fisher 158,223 sh (-1.99%)
Jim Simons 472,952 sh (-33.64%)
Steven Cohen 448,200 sh (-92.15%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2018-03-31 New Buy0.16%$12.59 - $18.4 $ 19.5522%526,500
Leon Cooperman 2018-03-31 New Buy0.12%$12.59 - $18.4 $ 19.5522%200,000
Ken Fisher 2018-03-31 Reduce -1.99%$12.59 - $18.4 $ 19.5522%158,223
Ken Fisher 2017-12-31 Add 20.31%$10.26 - $12.97 $ 19.5572%161,433
Ken Fisher 2017-06-30 Add 71.99%$6.96 - $9.07 $ 19.55139%134,180
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:SZSE:002603, NAS:CBPO, NAS:ONCE, NAS:TSRO, SHSE:600161, SZSE:000990, XSWX:IDIA, NAS:HALO, NAS:IMMU, XBRU:ARGX, XTER:MOR, SZSE:002821, SZSE:300009, XSWX:GALE, NAS:ASND, NAS:FOLD, NYSE:EBS, ROCO:4147, NAS:RARE, NAS:PBYI » details
Traded in other countries:AR2.Germany,
Headquarter Location:USA
Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its clinical stage drugs include Binimetinib, Encorafenib, Selumetinib, Tucatinib/ONT-380, ARRY-382, LOXO-292 and LOXO-195 among others. The company has geographical presence in North America, Europe and Asia Pacific.

Top Ranked Articles about Array BioPharma Inc

Array BioPharma to Present Overall Survival Results from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the ESMO 20th World Congress on Gastrointestinal Cancer
Array BioPharma Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with BRAF-mutant Advanced Melanoma
Array BioPharma To Present at the Jefferies 2018 Global Healthcare Conference
Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual Meeting
Array Biopharma To Present At The Bank Of America Merrill Lynch 2018 Health Care Conference
Array BioPharma Reports Financial Results For The Third Quarter of Fiscal 2018
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2018 On May 9, 2018
Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology
Array BioPharma To Present At The Cowen 38th Annual Healthcare Conference
New Research Coverage Highlights Timken Steel, National Health Investors, Donaldson, Array BioPharma, Impax Laboratories, and Baxter International — Consolidated Revenues, Company Growth, and Expectations for 2018

Ratios

vs
industry
vs
history
PB Ratio 15.52
ARRY's PB Ratio is ranked lower than
87% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ARRY: 15.52 )
Ranked among companies with meaningful PB Ratio only.
ARRY' s PB Ratio Range Over the Past 10 Years
Min: 3.52  Med: 15.87 Max: 135.59
Current: 15.52
3.52
135.59
PS Ratio 21.79
ARRY's PS Ratio is ranked lower than
63% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARRY: 21.79 )
Ranked among companies with meaningful PS Ratio only.
ARRY' s PS Ratio Range Over the Past 10 Years
Min: 1.44  Med: 7.65 Max: 24.4
Current: 21.79
1.44
24.4
EV-to-EBIT -33.39
ARRY's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. ARRY: -33.39 )
Ranked among companies with meaningful EV-to-EBIT only.
ARRY' s EV-to-EBIT Range Over the Past 10 Years
Min: -43.4  Med: -5.95 Max: 351.4
Current: -33.39
-43.4
351.4
EV-to-EBITDA -34.07
ARRY's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. ARRY: -34.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -74.7  Med: -6.55 Max: 173.7
Current: -34.07
-74.7
173.7
EV-to-Revenue 22.00
ARRY's EV-to-Revenue is ranked lower than
61% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. ARRY: 22.00 )
Ranked among companies with meaningful EV-to-Revenue only.
ARRY' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 7.7 Max: 27.9
Current: 22
2.1
27.9
Current Ratio 5.73
ARRY's Current Ratio is ranked higher than
65% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. ARRY: 5.73 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3.08 Max: 7.86
Current: 5.73
0.81
7.86
Quick Ratio 5.73
ARRY's Quick Ratio is ranked higher than
66% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. ARRY: 5.73 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3.06 Max: 7.55
Current: 5.73
0.81
7.55
Days Sales Outstanding 93.65
ARRY's Days Sales Outstanding is ranked lower than
63% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. ARRY: 93.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.61  Med: 50.33 Max: 497.21
Current: 93.65
4.61
497.21
Days Payable 80.31
ARRY's Days Payable is ranked higher than
62% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. ARRY: 80.31 )
Ranked among companies with meaningful Days Payable only.
ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 76.12 Max: 159.87
Current: 80.31
37.58
159.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.10
ARRY's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ARRY: -9.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARRY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.3  Med: -11.65 Max: -4.2
Current: -9.1
-111.3
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 19.95
ARRY's Price-to-Net-Cash is ranked lower than
75% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. ARRY: 19.95 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ARRY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.76  Med: 7.69 Max: 141.11
Current: 19.95
2.76
141.11
Price-to-Net-Current-Asset-Value 16.03
ARRY's Price-to-Net-Current-Asset-Value is ranked lower than
77% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. ARRY: 16.03 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ARRY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.24  Med: 7.57 Max: 418.5
Current: 16.03
2.24
418.5
Price-to-Tangible-Book 15.52
ARRY's Price-to-Tangible-Book is ranked lower than
81% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. ARRY: 15.52 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARRY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.14  Med: 4.71 Max: 123.09
Current: 15.52
1.14
123.09
Price-to-Median-PS-Value 2.85
ARRY's Price-to-Median-PS-Value is ranked lower than
88% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. ARRY: 2.85 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 0.91 Max: 2.88
Current: 2.85
0.19
2.88
Earnings Yield (Greenblatt) % -2.99
ARRY's Earnings Yield (Greenblatt) % is ranked higher than
60% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. ARRY: -2.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -95.2  Med: -13.95 Max: 5
Current: -2.99
-95.2
5

More Statistics

Revenue (TTM) (Mil) $172.11
EPS (TTM) $ -0.68
Beta2.10
Volatility55.38%
52-Week Range $7.15 - 20.18
Shares Outstanding (Mil)210.64

Analyst Estimate

Jun18 Jun19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.83 -0.82
EPS without NRI ($) -0.83 -0.82
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}